Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

Similar documents
Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

KNR Constructions Robust Performance on Execution Ramp-up

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Inox Wind BUY. Performance Highlights. CMP Target Price `390 `505. 2QFY2016 Result Update Capital Goods. 3 year price chart

KEC International Ltd.

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

MARKET RECAP. Instrument Close

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

ABB LTD (INDIA) RESEARCH

Ramco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360

Institutional Equities

Sonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.

Axis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018

Balkrishna Industries

INOX WIND LIMITED Q2FY18 INVESTOR UPDATE

Ambuja Cements. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.225. Rs. 195

PGCIL Order Inflow Analysis

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Colgate-Palmolive (India)

Gillette India. Institutional Equities. 1QFY18 Result Update

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

Bajaj Finance Limited (BFL) NBFC. BUY Rating as per Large Cap 12 months investment period RETAIL EQUITY RESEARCH

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

Key estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,

Bank of Baroda (BOB) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH

Jamna Auto Industries

ICICI BANK Ltd. BUY CMP (Rs.) 334 Target (Rs.) 382 Potential Upside 15% Tide set to turn favourably... For private circulation only

ICICI Bank Banking BUY RETAIL EQUITY RESEARCH

Healty cigarette-driven growth

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Buy Rating as per Mid Cap 12months investment period

Dalmia Bharat Enterprises

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Century Plyboards (India)

Key estimate revision. Financial summary. Year

State Bank of India (SBI)

ITC Ltd. BUY CMP (Rs.) 304 Target (Rs.) 336 Potential Upside(%) 11% Valuation: Investment Rationale. For private circulation only

RBL Bank Ltd. Banking. ACCUMULATE Rating as per Mid Cap 12 months investment period RETAIL EQUITY RESEARCH

Amber Enterprises India Ltd

Suzlon Energy Ltd RESULT UPDATE 16th August, 2017

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

Crompton Greaves Consumer Electricals

Jubilant Foodworks. CMP: INR1,051 TP: INR1,054 Neutral

BLS International Services

Larsen & Toubro Ltd.

Cummins India Ltd Bloomberg Code: KKC IN

BUY Rating as per Largecap 12months investment period

Pidilite Industries Ltd

Apollo Hospitals Enterprise Ltd.

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Fineotex Chemical Ltd

HDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11%

BUY. ICICI Bank RETAIL EQUITY RESEARCH. Banking. ddd******* GEOJIT Research. Strong traction in retail segment continues

Transcription:

Recommendation Range STOP LOSS Target 825-833 775 960 Jubilant FoodWorks Sector - FMCG Background & Business Jubilant FoodWorks (JFL) a Jubilant Bhartia Group Company incorporated in 1995 is India s largest and fastest growing food service company. JFL along with its subsidiary operates Domino s Pizza brand with the exclusive rights for India, Nepal, Bangladesh and Sri Lanka. The company operated 1081 Dominos and 73 Dunkin Donut stores by end of 2QFY17. Investment Rationale 1 Year Stock Price Performance 1,400 1,300 1,200 Expected Recovery in Same Store Sales Growth (SSSG): SSSG remains the key for meaningful turnaround in JFL s performance. Although demonetization drive is likely to dampen JFL s performance in 2HFY17E, we believe that gradual recovery in consumer confidence, increased promotions, moderation in competition and success of new products could take SSSG to higher levels. 1,100 1,000 900 Strong Cash Generation: While JFL s operating cash generation has fallen from 15% to 10% of sales in past four years, it still remains strong as JFL generates operating cash in the excess of Rs2.5bn annually. Notably, in past four years JFL has doubled its store count from 550 to 1,100 and added several commissaries without adding any debt on its books, which is impressive. 800 700 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Impressive Cost Control: Although revenues have been impacted materially in the past four years on account of poor SSS growth and additional impact of Dunkin Donuts, JFL has maintained solid control over its costs. Looking ahead, while we expect JFL to continue on the cost rationalization trajectory, recovery in SSS holds the key for any visible uptick in operating performance and so does the stock price. Note: *CMP as on January 16, 2017 Key Figure Food Aggregators Not a Major Concern: We believe that though the food aggregators provide additional delivery choices to consumers, their impact on JFL s business model is limited considering its increased footprints and impeccable delivery record. Outlook & Valuation JFL has been undergoing a tumultuous time for last few quarters marked by stagnant SSSG, pressure on margins and high level exits with which the stock has corrected by 40% in past 1 year and by 22% in past 3 months. Despite near-term uncertainties, we believe that risk reward ratio is turning to be favourable, while revival in SSSG could be the most vital factor to watch out for, going forward. Risks Delay in recovery in Same Store Sales to impact revenue, margins and net profit Poor performance of Dunkin Donuts for extended period would dampen our estimates Mar (Rs mn) FY16 FY17E FY18E Revenues 24,095 26,088 30,417 EBITDA 2,844 2,668 3,628 EBITDA MARGIN % 11.8 10.2 11.9 Adj.PAT 1,146 869 1399 ROE (%) 14.9 10.6 15.0 Market Cap ( Rsbn/US$mn ) 55.0/8.0 Current Price 833 Target Price 960 Promoters / Public & Others 45/55 FY18E P/E (x) 39.1 Revenues CAGR (FY16-18 %) 12.4 PAT CAGR (FY16-18 %) 10.5 Key Ratios FY16 FY17E FY18E P/E (x) 47.9 63.1 39.1 P/BV (x) 7.1 6.7 5.9 EV/EBITDA (x) 19.0 20.2 14.9 Source: Company, RSec Estimates Research Team; Contact: (022) 33201202; Email: rsec.research@rcap.co.in 1

Recommendation Range STOP LOSS Target 179-182 168 220 INOX Wind Background & Business Inox Wind (INXW) promoted by Gujarat Fluorochemicals is a fully integrated player in wind energy market with state-of-theart manufacturing plants at Una (HP) for Hubs & Nacelles and Rohika (Gujarat) for Blades & Tubular Towers. It manufactures key components for the Wind Turbine Generator. It manufactures the key components of the Wind Turbine Generator (WTG) to ensure high quality based on the most advanced technology, reliability of performance, and cost competitiveness. Investment Rationale Strong Order Book: As of 2QFY17, INXW had order book for WTGs with aggregate capacity of 1,346MW. It has >4,500MW of project sites as of 2QFY17, which oers good visibility for next 6-7 years. The Company has expanded presence in Andhra Pradesh & Karnataka with a sizable project site inventory. Comprehensive Turnkey Solutions for Wind Farm Projects: INXW provides turnkey solutions for wind firm projects including resource assessment, site acquisition, infrastructure development, erection and commissioning, long-term O&M of wind power projects. It has a perpetual license to use proprietary technology of AMSC an Austria-based wind energy technology company to manufacture 2MW WTGs in India. Renewed Thrust on Renewable Energy: The Government plans to add 175GW renewable power with wind power s share at 60GW by 2022 from 23GW as of FY15. Apart from assigning priority-sector status to renewable energy (up to Rs0.15bn) to ensure cheaper funding, several other measures i.e. Accelerated Depreciation, Generation-based Incentives & Renewable Energy Certificates have been reintroduced, which augur well for INOW. Outlook & Valuation We believe that strong outstanding order book and impeccable execution capabilities will continue to drive INXW s profitability and healthy returns in next few years. However, with the recent Gujarat Wind Policy and feed-in tari order in place, we expect power plant commissioning will pick-up pace from 4QFY17E onwards, which will result in lower working capital by 2HFY17E. Risks Any inordinate delays or defaults in customer payments, and Deterioration in net working capital days would lead to negative operating cash flows and higher debt. Mar (Rsmn) FY16 FY17E FY18E Revenues 44,141 44,331 48,730 EBITDA 6,902 6,206 7,212 EBITDA MARGIN % 15.6 14.0 14.8 Adj.PAT 4,519 4,007 4,898 ROE (%) 24.5 18.2 18.4 1 Year Stock Price Performance 400 350 300 250 200 150 Sector - Capital Goods Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Note: *CMP as on January 16, 2017 Key Figure Market Cap ( Rsbn/US$mn ) 40.3/5.9 Current Price 182.0 Target Price 220.0 Promoters / Public & Others 85.6/14.4 FY18E P/E (x) 8.2 Revenues CAGR (FY16-18 %) 5.1 PAT CAGR (FY16-18 %) 4.1 Key Ratios FY16 FY17E FY18E P/E (x) 8.9 10.1 8.2 P/BV (x) 2.2 1.8 1.5 EV/EBITDA (x) 7.2 7.7 6.5 Source: Company, RSec Estimates Research Team; Contact: (022) 33201202; Email: rsec.research@relianceada.com 2

Recommendations Summary Open Positions Stock Symbol Sector Reco Date Reco Price CMP SL Target Remarks JUBLFOOD FMCG 17-Jan-17 825-833 833 775 960 BUY INOXWIND Capital Goods 17-Jan-17 179-182 182 168 220 BUY ASIANPAINT FMCG 04-Jan-17 888-897 935 852 1010 HOLD Closed Positions Stock Symbol Sector Reco Date Reco Price Exit Price Exit Date Return % Remarks NBCC Infrastructure 21-Jun-16 186 213 07-Jul-16 14.3% Booked Profit PERSISTENT IT 21-Jun-16 696 650 18-Jul-16-6.6% Booked Loss SUNPHARMA Pharma 02-Jul-16 763 801 21-Jul-16 5.0% Booked Profit PFS NBFC 02-Jul-16 39 38 16-Aug-16-2.1% Booked Loss CROMPTON Capital Goods 15-Jul-16 144 156 28-Jul-16 8.6% Booked Profit UPL Agrochemicals 15-Jul-16 566 616 29-Jul-16 8.9% Booked Profit ABFRL Retailing 30-Jul-16 145 162 18-Aug-16 11.6% Booked Profit KEC Capital Goods 30-Jul-16 143 133 07-Sep-16-7.0% Booked Loss MGL Oil-Gas 17-Aug-16 537 595 23-Aug-16 10.8% Booked Profit SUNPHARMA Pharma 17-Aug-16 783 733 29-Sep-16-6.4% Booked Loss INFY IT 01-Sep-16 1036 1064 19-Sep-16 2.7% Booked Profit BAJAJCORP Consumer 01-Sep-16 400 406 14-Oct-16 1.4% Booked Profit AUROPHARMA Pharma 16-Sep-16 783 859 23-Sep-16 9.6% Booked Profit NAVKARCORP Logistics 16-Sep-16 200 184 29-Sep-16-8.0% Booked Loss ABFRL Retailing 03-Oct-16 138 148 21-Oct-16 6.9% Booked Profit Continued... 3

Closed Positions Stock Symbol Sector Reco Date Reco Price Exit Price Exit Date Return % Remarks AMBUJACEM Cement 03-Oct-16 252 238 03-Nov-16-5.6% Booked Loss ASHOKLEY Auto 17-Oct-16 81 85 20-Oct-16 5.1% Booked Profit INFY IT 17-Oct-16 1027 980 02-Nov-16-4.6% Booked Loss TECHM IT 16-Nov-16 431 454 17-Nov-16 5.2% Booked Profit CADILAHC Pharma 16-Nov-16 358 386 23-Nov-16 7.7% Booked Profit FEDERALBANK Banking 01-Dec-16 71 65 23-Dec-16-8.5% Booked Loss ASHOKLEY Auto 16-Dec-16 78 80 30-Dec-16 3.2% Booked Profit TITAN FMCG 16-Dec-16 315 327 30-Dec-16 4.0% Booked Profit CADILAHC Pharma 04-Jan-17 355 377 06-Jan-17 6.2% Booked Profit CROMPTON Capital Goods 01-Dec-16 148 156 13-Jan-17 5.5% Booked Profit 4

Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or oering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, ailiates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, ailiates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely aected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces aecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be aected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may aect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an oicer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. (Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: CDSL IN-DP-257-2016 IN-DP- SDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 5